Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Increase in negative charge of 68Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules.

Rinne SS, Dahlsson Leitao C, Gentry J, Mitran B, Abouzayed A, Tolmachev V, Ståhl S, Löfblom J, Orlova A.

Sci Rep. 2019 Nov 27;9(1):17710. doi: 10.1038/s41598-019-54149-3.

2.

Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer.

Mitran B, Varasteh Z, Abouzayed A, Rinne SS, Puuvuori E, De Rosa M, Larhed M, Tolmachev V, Orlova A, Rosenström U.

Cancers (Basel). 2019 Sep 14;11(9). pii: E1371. doi: 10.3390/cancers11091371.

3.

Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates.

Ding H, Altai M, Rinne SS, Vorobyeva A, Tolmachev V, Gräslund T, Orlova A.

Cancers (Basel). 2019 Aug 14;11(8). pii: E1168. doi: 10.3390/cancers11081168.

4.

Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer.

Abouzayed A, Yim CB, Mitran B, Rinne SS, Tolmachev V, Larhed M, Rosenström U, Orlova A.

Pharmaceutics. 2019 Jul 23;11(7). pii: E358. doi: 10.3390/pharmaceutics11070358.

5.

Indirect Radioiodination of DARPin G3 Using N-succinimidyl-Para-Iodobenzoate Improves the Contrast of HER2 Molecular Imaging.

Vorobyeva A, Schulga A, Rinne SS, Günther T, Orlova A, Deyev S, Tolmachev V.

Int J Mol Sci. 2019 Jun 21;20(12). pii: E3047. doi: 10.3390/ijms20123047.

6.

Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177 Lu-DOTAGA-PEG2 -RM26.

Mitran B, Rinne SS, Konijnenberg MW, Maina T, Nock BA, Altai M, Vorobyeva A, Larhed M, Tolmachev V, de Jong M, Rosenström U, Orlova A.

Int J Cancer. 2019 Dec 15;145(12):3347-3358. doi: 10.1002/ijc.32401. Epub 2019 May 23.

7.

Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake.

Rosestedt M, Andersson KG, Rinne SS, Leitao CD, Mitran B, Vorobyeva A, Ståhl S, Löfblom J, Tolmachev V, Orlova A.

Sci Rep. 2019 May 1;9(1):6779. doi: 10.1038/s41598-019-43145-2.

8.

Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of 68Ga-Labeled Tracers.

Dahlsson Leitao C, Rinne SS, Mitran B, Vorobyeva A, Andersson KG, Tolmachev V, Ståhl S, Löfblom J, Orlova A.

Int J Mol Sci. 2019 Mar 2;20(5). pii: E1080. doi: 10.3390/ijms20051080.

9.

Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111.

Rinne SS, Leitao CD, Mitran B, Bass TZ, Andersson KG, Tolmachev V, Ståhl S, Löfblom J, Orlova A.

Sci Rep. 2019 Jan 24;9(1):655. doi: 10.1038/s41598-018-36827-w.

10.

Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs.

Altai M, Leitao CD, Rinne SS, Vorobyeva A, Atterby C, Ståhl S, Tolmachev V, Löfblom J, Orlova A.

Cells. 2018 Oct 11;7(10). pii: E164. doi: 10.3390/cells7100164.

11.

Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model.

Mitran B, Güler R, Roche FP, Lindström E, Selvaraju RK, Fleetwood F, Rinne SS, Claesson-Welsh L, Tolmachev V, Ståhl S, Orlova A, Löfblom J.

Theranostics. 2018 Aug 7;8(16):4462-4476. doi: 10.7150/thno.24395. eCollection 2018.

12.

Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab.

Orlova A, Bass TZ, Rinne SS, Leitao CD, Rosestedt M, Atterby C, Gudmundsdotter L, Frejd FY, Löfblom J, Tolmachev V, Ståhl S.

Mol Pharm. 2018 Aug 6;15(8):3394-3403. doi: 10.1021/acs.molpharmaceut.8b00393. Epub 2018 Jul 25.

PMID:
29995421
13.

Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression.

Rosestedt M, Andersson KG, Mitran B, Rinne SS, Tolmachev V, Löfblom J, Orlova A, Ståhl S.

Int J Oncol. 2017 Dec;51(6):1765-1774. doi: 10.3892/ijo.2017.4152. Epub 2017 Oct 11.

PMID:
29039474

Supplemental Content

Loading ...
Support Center